Stocks
Oragenics, Inc.OGEN
AMEXHealthcareBiotechnology$0.20
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing treatments for infectious diseases and oral mucositis, with a focus on its lead candidate for Clostridioides difficile infection. The company has faced significant dilution and financing challenges, making it a high-risk speculative stock. Investors track OGEN for its pipeline progress and potential regulatory milestones.
52W Range: $0.17-$1.15
Congressional Interest in Oragenics, Inc. (OGEN)
1 member of Congress has disclosed 1 trade in Oragenics, Inc. (OGEN), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading OGEN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2011-09-11 | JAMES B. RENACCI | buy | $3,327.50 |